Claudin 18.2-targeted CAR T-cell therapy (satri-cel) demonstrated durable peritoneal disease control in three phase 1 patients with advanced gastric cancer and peritoneal metastasis, investigators reported based on trial NCT03874897. All three patients had confirmed high CLDN18.2 expression. The report highlights that peripheral CAR T-cell clearance occurred rapidly—circulating cells became nearly undetectable around day 30—while clinical and radiologic benefit persisted at the peritoneal site. In one patient, satri-cel enabled conversion surgery after eight months, with subsequent resection of ovarian metastases and no further progression reported. The results reinforce the need for peritoneal-specific readouts in CLDN18.2 CAR T development and support ongoing exploration of dose, manufacturing, and conditioning strategies to improve local persistence.
Get the Daily Brief